ClinicalTrials.gg
TerminatedNCT06549790Updated Nov 19, 2026

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1 interventional study of NMS-03597812 in Relapsed/Refractory Acute Myeloid Leukemia, sponsored by Nerviano Medical Sciences. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Nerviano Medical Sciences · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
The decision about study closure has not been based on safety profile or clinical data of NMS- 03597812 but for strategic decisions regarding the company's assets.
Updated Nov 19, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
1,232nd of 1,908
23 · median 35
Started
2024
with 70 others
Phase 1
772 of 2,138
127 open now
Registered
1,990th of 2,138
by date

Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 1,232nd largest by enrollment of the 1,908 interventional ones that give a count, is one of 71 that started in 2024, is one of 772 in phase 1, and was the 1,990th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

304 more — sign in →

All 309 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, including a subset of patients with TP53 mutations. It is anticipated that combination with venetoclax will be further evaluated following a future protocol amendment, once the Recommended Range Dose (RDR) as single agent has been defined.

03

Conditions studied

  • Relapsed/Refractory Acute Myeloid Leukemia

Keywords

  • Leukemia
  • Relapsed/Refractory Acute Myeloid Leukemia
  • TP53 mutations
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of /relapsed (R/R) AML according to 2022 ELN recommendation:

Phase Ia

  • single agent dose escalation of NMS-03597812: R/R AML patients who have exhausted standard therapy: a) prior fit patients to intensive chemotherapy (IC): failed at least one cycle of IC in front-line therapy or b) prior unfit to IC: failed at least 2 cycles of hypomethylating agents (HMA)/venetoclax combination therapy, or at least 4 cycles of HMA monotherapy; c) patients must have failed all other approved therapies for which they are eligible, including FLT3 inhibitors, IDH1/2 inhibitors, and CD33 directed therapy

Phase Ib

  • Cohort A: single agent in R/R AML TP53mt patients who have exhausted standard therapy: a) prior unfit to intensive chemotherapy (IC): failed at least 2 cycles of HMA/venetoclax combination therapy, or at least 4 cycles of HMA monotherapy; b) patients must have failed all other approved therapies for which they are eligible, including FLT3 inhibitors, IDH1/2 inhibitors, and CD33 directed therapy
  • Cohort B: single agent in R/R AML TP53wt patients who have exhausted standard therapy: a) prior fit patients to intensive chemotherapy (IC): failed at least one cycle of IC in front-line therapy or b) prior unfit to IC: failed at least 2 cycles of HMA/venetoclax combination therapy, or at least 4 cycles of HMA monotherapy; c) patients must have failed all other approved therapies for which they are eligible, including FLT3 inhibitors, IDH1/2 inhibitors, and CD33 directed therapy
  • Adult (age ≥ 18 years) patients
  • (ECOG) performance status ≤ 2
  • Unless agreed with sponsor, the interval from prior antitumor treatment should be at least 2 weeks or 5 half-lives, whichever is longer, other than hydroxyurea
  • All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to version 5.0 Grade≤ 1
  • Adequate organ function
  • Must use highly effective or true abstinence. Female patients must be surgically sterile or, if patient is of , must agree to use effective contraception of therapy and in the following 210 days after discontinuation of study treatment. Since NMS-03597812 has potential induction of , women of childbearing potential must be advised that hormonal contraceptives might lose efficacy and must use alternate form of highly effective contraception. Male patients must be surgically sterile or must agree to use highly effective contraception or true abstinence during the period of therapy and in the following 120 days for male patients who must refrain from donating sperm during this period after discontinuation of study treatment.
  • Capability to swallow capsules intact (without chewing, crushing, or opening)
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study indications or procedures
  • Signed and dated Independent Ethics Committee (IEC) or Institutional Review Board (IRB)-approved form indicating that the patient is aware of the neoplastic nature of his/her disease and has been informed of the procedures to be followed, the nature of the therapy, potential benefits, side effects, discomforts, risks, and alternative treatments.

Exclusion criteria

Exclusion Criteria:

  • Current enrollment in another interventional clinical study unless only participating in survival follow up
  • White blood cells (WBC) count >20×10\^3/microliter (μL). However, patients can be treated with hydroxyurea and/or leukapheresis prior to study treatment start to reduce the WBC to ≤ 20×10\^3/μL to enable eligibility for study drug dosing.
  • Diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia
  • Currently active second , except for adequately treated basal or squamous cell skin cancer and/or cone biopsied in situ carcinoma of the cervix uteri and/or superficial bladder cancer.
  • Patients with known leukemia involvement of central nervous system (CNS).
  • Hematopoietic stem cell transplantation () within 3 months of treatment start and/or persistent non- hematologic toxicities of Grade ≥2 related to the transplant
  • Active acute or chronic (GVHD) requiring treatment
  • Patients with interval ≥ 470 milliseconds or with risk factors for torsade de pointes (e.g., uncontrolled heart failure, uncontrolled hypokalemia, history of prolonged QTc interval or family history of long QT syndrome). For patients receiving treatment with concomitant medications known to prolong the QTc interval, replacement with another treatment needs to be considered. If replacement or discontinuation is not clinically feasible, a careful risk/benefit evaluation should be performed prior to enrollment.
  • Pregnancy. All female patients with must have a negative pregnancy test (serum or urine) within the screening period prior to start of study drug.
  • Breast-feeding or planning to breast feed during the study or within 90 days after study treatment.
  • Known active gastrointestinal disease (eg, gastro-duodenal ulcer, gastrectomy, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.
  • Patient who are receiving concomitant medications with antacids (proton pump inhibitors are strictly prohibited; calcium carbonate antacids are only allowed 6 hours prior to a dose or 1 hour after). Note: exclusion criterion not applicable to optional backfill cohort for investigation of drug-drug interaction with antiacids.
  • Patient who are receiving concomitant medications that are strong inducers or inhibitors of (with the exception of azole antifungals) and CYP2C9 that cannot be replaced with alternative therapy.
  • Patients who are receiving concomitant medications that are sensitive substrates of CYP3A4,CYP2D6, CYP1A2 and CYP2B6 with narrow therapeutic window that cannot be replaced with alternative therapy. Drugs with broad therapeutic indices may still be acceptable.
  • Patients who are receiving concomitant medications that are strong or moderate P-gp inhibitors that cannot be replaced with alternative therapy.
  • Major surgery within 4 weeks before study treatment start.
  • Radiotherapy within 4 weeks before study treatment start. However, if the radiation portal covered ≤5 % of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy.
  • History of necrotic pancreatitis or acute severe pancreatitis, requiring medical intervention and/or hospitalization, in the previous 6 months before study treatment start.

NOTE: Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    NMS-03597812

    Dose escalation (Phase Ia): Administered orally once daily (28 consecutive days) in repeated 4-week cycles. Each cycle is 28 days. Expansion cohorts (Phase Ib, Cohorts A and B): The dose expansion may comprise up to a total of 2 single arms of NMS-03597812 as single agent: * Cohort A: in patients with TP53mt relapsed/refractory acute myeloid leukemia (R/R AML) prior unfit to intensive chemotherapy (IC) who have exhausted standard treatment options * Cohort B: in prior fit or unfit patients to IC with TP53wt R/R AML who have exhausted standard treatment options Backfill cohorts: Optional backfill cohorts may be opened at any time during the conduct of the trial to further evaluate the following items: NMS-03597812 dosing alone, pharmacokinetic (PK), drug-drug interactions, food effects, biomarkers and QTc for NMS-03597812 as single agent.

    Drug: NMS-03597812

Interventions

  • DrugNMS-03597812

    Route of Administration: Oral

06

What researchers measure

Primary outcomes

  1. Phase Ia (escalation) - Number of Participants with Adverse Events (AEs)

    Evaluation of AE frequency and severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] Version 5.0), including dose limiting toxicities (DLTs), laboratory measurements, electrocardiogram (ECG) measurements, vital sign measurements

    Time frame: Screening (Day ≤28) up to 28-day follow-up after end of treatment (Approximately 13 months)

  2. Phase Ib (expansion) - Complete Remission (CR) rate

    Complete Remission (CR) rate, as defined by the Investigators based on the 2022 European LeukemiaNet (ELN) recommendations

    Time frame: From date of treatment initiation up to hematological relapse (Approximately 12 months)

Secondary outcomes

  1. Phase Ia - Complete remission (CR) rate

    Complete Remission (CR) rate, as defined by the Investigators based on the 2022 European LeukemiaNet (ELN) recommendations.

    Time frame: From date of treatment initiation up to hematological relapse (Approximately 12 months)

  2. Phase Ia - Maximum concentration (Cmax) of NMS-0597812

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Cycle 1 (each cycle is 28 days): Day 1 and Day 15

  3. Phase Ia - Related time of achievement of occurrence of Cmax (tmax) of NMS-0597812

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Cycle 1 (each cycle is 28 days): Day 1 and Day 15

  4. Trough concentration (Cτ) area under concentration versus time up to 24 hours (dosing interval) of NMS-0597812

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Cycle 1 (each cycle is 28 days): Day 1 and Day 15

  5. Phase Ia - Half-life of the terminal phase (t½,z) of NMS-0597812

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Cycle 1 (each cycle is 28 days): Day 1 and Day 15

  6. Phase Ia - Plasma clearance (CL) of NMS-0597812

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Cycle 1 (each cycle is 28 days): Day 1 and Day 15

  7. Phase Ia - Volume of distribution (Vss) of NMS-0597812

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Cycle 1 (each cycle is 28 days): Day 1 and Day 15

  8. Phase Ia - Accumulation ratio (Rac) of NMS-0597812

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Cycle 1 (each cycle is 28 days): Day 15

  9. Phase Ia - Renal clearance (CLR) of NMS-03597812 excreted in urine (data permitting)

    Urine samples will be collected and used for pharmacokinetics assessments

    Time frame: Cycle 1 (each cycle is 28 days): Day 1 and Day 15

  10. Phase Ia - Cumulative amount recovered unchanged in the urine (Ae) of NMS-03597812 (data permitting)

    Urine samples will be collected and used for pharmacokinetics assessments

    Time frame: Cycle 1 (each cycle is 28 days): Day 1 and Day 15

  11. Phase Ia - Cumulative amount recovered unchanged in the urine expressed as a fraction of administered dose (Ae%) of NMS-03597812 (data permitting)

    Urine samples will be collected and used for pharmacokinetics assessments

    Time frame: Cycle 1 (each cycle is 28 days): Day 1 and Day 15

  12. Phase Ib - Complete remission (CR) + complete remission with partial hematologic recovery (CRh) rate

    Number and percentage of patients who achieve CR and CRh as best response

    Time frame: From date of treatment initiation up to hematological relapse (Approximately 12 months)

  13. Phase Ib - Complete remission (CR) + Complete remission with incomplete hematologic recovery (CRi) rate

    Number and percentage of patients who achieve CR and CRi as best response

    Time frame: From date of treatment initiation up to hematological relapse (Approximately 12 months)

  14. Phase Ib - Complete remission (CR) + Complete remission with partial hematologic recovery (CRh) + complete remission with incomplete hematologic recovery (CRi) rate

    Number and percentage of patients who achieve CR, CRh and CRi as best response

    Time frame: From date of treatment initiation up to hematological relapse (Approximately 12 months)

  15. Phase Ib - Overall Response Rate (ORR: CR + CRh + CRi + MLFS + PR)

    ORR: Complete remission (CR) + Complete remission with partial hematologic recovery (CRh) + Complete remission with incomplete hematologic recovery (CRi) + Morphological leukemia-free state (MLFS) + Partial remission (PR) Defined as the number and percentage of patients who achieve CR, CRh, CRi, MLFS and PR as best response in the analysis population

    Time frame: From date of treatment initiation up to hematological relapse/progressive disease (Approximately 12 months)

  16. Phase Ib - Overall Survival (OS)

    Defined as the time from the date of start of treatment until the date of death from any cause. Patient who was not known to have died by the end of study will be censored at the date of last recorded date.

    Time frame: First dose to the date of death from any cause or start of a new anti-cancer therapy, whichever comes first (Approximately 18 months)

  17. Phase Ib - Duration of Response (DoR)

    Defined as the time from the date of first response (CR, CRh, or CRi) until the date of documented hematologic relapse or death due to progression. DOR will be also calculated for overall response, including patients who achieve MLFS or PR as best response during the treatment.

    Time frame: From the date of first response (CR, CRh, or CRi) to the date of hematological relapse or death due to progression, whichever comes first. (Approximately 12 months)

  18. Phase Ib - Event-Free Survival (EFS)

    Defined as the time from the date of treatment initiation to the date of hematological relapse from CR, CRh, or CRi, or death from any cause, whichever comes first.

    Time frame: From the date of treatment initiation to the date of hematological relapse from CR, CRh, or CRi, date of treatment failure, or death from any cause, whichever comes first. (Approximately 18 months)

  19. Phase Ib - Relapse-free Survival (RFS)

    Measured only for patients achieving CR, CRh, or CRi, and it is defined as the time from the date of first achievement of remission until the date of hematologic relapse or death from any cause.

    Time frame: Date of first achievement of remission until the date of hematologic relapse or death from any cause, whichever comes first (Approximately 12 months).

  20. Phase Ib - Proportion of patients bridged to hemopoietic stem cell transplantation (HSCT)

    Time frame: From date of treatment initiation up to end of study (Approximately 18 months)

  21. Phase Ib - Rate of conversion from transfusion-dependence to transfusion independence

    Time frame: From date of treatment initiation up to end of study (Approximately 18 months)

  22. Phase Ib - AE frequency and severity

    AE frequency and severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] Version 5.0), laboratory, ECG and vital sign measurements

    Time frame: Screening (Day ≤28) up to 28-day follow-up after end of treatment (Approximately 13 months)

07

Study locations

6 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2024 to primary completion in Sep 2026, 23 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Sep 2029 → Sep 2026 and completion May 2030 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Aug 12, 2024
StartActual
Oct 16, 2024
Primary completionActual
Sep 24, 2026was Sep 2029
CompletionActual
Oct 5, 2026was May 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated The decision about study closure has not been based on safety profile or clinical data of NMS- 03597812 but for strategic decisions regarding the company's assets.
changed Nov 19, 2026
Sites
1 site removed
Show 1 removed
  • Mayo Clinic Cancer Center (MCCC) - Rochester · Rochester, United States
Nov 19, 2026
Primary completion
Sep 15, 2029→Sep 24, 2026 (actual)
Nov 19, 2026
Study completion
May 15, 2030→Oct 5, 2026 (actual)
Nov 19, 2026
Enrollment
124 (estimated)→23 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Terminated
    Why stopped The decision about study closure has not been based on safety profile or clinical data of NMS- 03597812 but for strategic decisions regarding the company's assets.
    1 site removed
    Show 1 removed
    • Mayo Clinic Cancer Center (MCCC) - Rochester · Rochester, United States
    Primary completion Sep 15, 2029→Sep 24, 2026 (now actual)
    Study completion May 15, 2030→Oct 5, 2026 (now actual)
    Enrollment 124 (estimated)→23 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06549790
Lead sponsor
Nerviano Medical Sciences
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Oct 16, 2024
Primary completion
Sep 24, 2026
Completion
Oct 5, 2026
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion